Stock Events

Stock Events

Cogent Biosciences 

$35.95
53
+$0.64+1.81% 08:47 Today

Statistics

Day High
35.35
Day Low
35.28
52W High
43.73
52W Low
11.6
Volume
83,601
Avg. Volume
-
Mkt Cap
6.13B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.64
-0.59
-0.55
-0.5
Expected EPS
-0.555987
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-328.94MNet Income

Analyst Ratings

54.40Average Price Target
The highest estimate is 55.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow COGT. It's not an investment recommendation.
Apple
14
AAPL
Amazon
13
AMZN
Microsoft
12
MSFT
Tesla
12
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the field of genetic and molecular therapies for cancer and other diseases.
Novartis
NVS
Mkt Cap286.78B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for cancer, directly competing in some of the same therapeutic areas as Cogent.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic diseases, competing in the rare disease space with Cogent.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is known for its work in treating cystic fibrosis and other genetic disorders, areas where Cogent could potentially compete.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals works on RNAi (RNA interference) therapies for genetic diseases, a competing technology in the genetic disease treatment space.
Beam Therapeutics
BEAM
Mkt Cap2.76B
Beam Therapeutics uses base editing, a form of gene editing, presenting direct competition in the genetic disease treatment market.
PTC Therapeutics
PTCT
Mkt Cap5.98B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including treatments for genetic disorders, competing in the same therapeutic areas as Cogent.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the genetic and rare disease market similar to Cogent.

About

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Show more...
CEO
Andrew R. Robbins
Employees
258
Country
United States
ISIN
US19240Q2012

Listings

BOATS
BOATS
COGT.BOATS
XNAS
US
COGT

0 Comments

Share your thoughts

FAQ

What is Cogent Biosciences stock price today?▼
The current price of COGT is $35.95 USD — it has increased by +1.81% in the past 24 hours. Watch Cogent Biosciences stock price performance more closely on the chart.
What is Cogent Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cogent Biosciences stocks are traded under the ticker COGT.
Is Cogent Biosciences stock price growing?▼
COGT stock has fallen by -6.91% compared to the previous week, the month change is a -7.81% fall, over the last year Cogent Biosciences has showed a +200% increase.
What is Cogent Biosciences market cap?▼
Today Cogent Biosciences has the market capitalization of 6.13B
When is the next Cogent Biosciences earnings date?▼
Cogent Biosciences is going to release the next earnings report on November 10, 2026.
What were Cogent Biosciences earnings last quarter?▼
COGT earnings for the last quarter are -0.52 USD per share, whereas the estimation was -0.55 USD resulting in a +6.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cogent Biosciences revenue for the last year?▼
Cogent Biosciences revenue for the last year amounts to 0 USD.
What is Cogent Biosciences net income for the last year?▼
COGT net income for the last year is -328.94M USD.
How many employees does Cogent Biosciences have?▼
As of August 21, 2026, the company has 258 employees.
In which sector is Cogent Biosciences located?▼
Cogent Biosciences operates in the Health & Wellness sector.
When did Cogent Biosciences complete a stock split?▼
The last stock split for Cogent Biosciences was on November 09, 2020 with a ratio of 1:4.
Where is Cogent Biosciences headquartered?▼
Cogent Biosciences is headquartered in WALTHAM, United States.